Cipla in the news

Four fundamentally strong companies including Cipla, with low debt and below-industry PE ratios, are highlighted as attractive long-term investments.

Cipla launched a new injectable drug for obesity and type-2 diabetes amid various corporate developments in major Indian companies.

Cipla launched Yurpeak, a new injectable drug for obesity and type 2 diabetes, distributing it across India with Lilly's support.

Cipla launched Yurpeak, a weekly tirzepatide injection for obesity and type 2 diabetes in India, partnering with Eli Lilly for supply and focusing on patient support.

Cipla launched Tirzepatide as Yurpeak in India, targeting diabetes and weight management with a strong focus on expanding reach beyond Eli Lilly's market.

Cipla launched Urpeik, a once-weekly injectable drug for obesity and type 2 diabetes, with rights from Eli Lilly after DCGI approval.

Key Indian companies including IndiGo, LIC, Prestige Estates, Tata Steel, and Cipla announced strategic moves and financial updates, with Cipla launching a new diabetes and obesity drug in India.

Cipla acquired Inzpera Healthsciences, a company specializing in wellness-focused therapeutic products, with legal representation from Fox Mandal & Associates and Tata Industries.

Cipla launched Yurpeak, a tirzepatide therapy for obesity and type 2 diabetes in India, boosting its stock by 1.5%.

Key market movers include Tata Steel's expansion, Cipla's new diabetes drug launch, Petronet LNG's financing, and major infrastructure contracts.

Cipla launched Yurpeak, a tirzepatide injectable for obesity and type 2 diabetes, expanding access across India with support from Lilly.

Cipla Ltd earned an ESG rating of 66 for FY 2024-25, reflecting its sustainable practices and potential investor appeal.

Cipla has been assigned an ESG rating of 66, as reported by Capital Market Publishers India, which offers comprehensive corporate databases and financial insights.

Cipla launched Yurpeak, a new injectable treatment for obesity and type 2 diabetes, in India through a partnership with Eli Lilly.

Cipla launched Yurpeak, a weekly injectable tirzepatide drug for obesity and type-2 diabetes, distributed in India through a partnership with Eli Lilly.

Cipla launched Yurpeak for obesity and type 2 diabetes, expanding its pharmaceutical product portfolio with strong global sales.

Cipla launched Yurpeak, a tirzepatide-based obesity drug, to expand access in smaller Indian towns, competing in a growing GLP-1 market led by Mounjaro and Wegovy.

Tata Steel expands capacity and acquires mining stakes; Cipla launches new diabetes and obesity drug Yurpeak in India; Ashoka Buildcon and Prestige Estates secure major project deals.

Venus Remedies received a final payment of 110 million rupees from Cipla, concluding their financial transaction.

Cipla's shares have doubled in five years with strong EPS growth and dividends boosting total returns, though recent gains have slowed.